Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

Figure 1.

Representative plots showing the KRAS mutation status of CTC-enriched specimens.

Graphs showed the ΔCt values (y axis) versus the CTC-enriched specimens (x axis) of mCRC patients (n = 31), healthy individuals (n = 16) and model samples spiked with 100 and 10 cells from cell lines (LS174T, SW403, KYSE410 and HCT116) harboring hotspot KRAS mutations c.35G>A; p.G12D (A), c.35G>T; p.G12V (B), c.38G>A; p.G13D (C) and c.34G>T; p.G12C (D). Cutoff threshold is represented by dot-line; specimens with ΔCt below the threshold are considered mutant; ΔCt = Ctmut probe (+PNA) – Ctwt probe (-PNA); NVD, no variant detected.

More »

Figure 1 Expand

Table 1.

Analytical sensitivity of KRAS mutation detection assay.

More »

Table 1 Expand

Table 2.

Cross reactivity pattern of KRAS mutation detection assay.

More »

Table 2 Expand

Table 3.

Pathological and clinical characteristics of mCRC patients.

More »

Table 3 Expand

Table 4.

KRAS mutation status in primary tumor and corresponding CTC-enriched samples in mCRC patients.

More »

Table 4 Expand